Finviz alternative · free
Finviz tells you which stocks crossed which threshold. Framler tells you which stocks score 0–100 across thirteen academic factors, how confident the model is in each call, and which patterns are firing right now — with every formula on a public methodology page.
Both are free. Different mental models.
Finviz screens by individual technical / fundamental thresholds. Framler combines thirteen peer-reviewed factor families (quality, value, momentum, PEAD, insider flow, NLP tone, options, accruals, short interest, sector momentum, spillover, microstructure, factor interaction) into one Bayesian-shrunk composite score. Picking with one number that has academic provenance is faster than picking with twenty filters that don't.
Every Framler score ships with a Mondrian conformal prediction interval — the model says "score 78, but expect ± 14 with 90% coverage on this regime / sector cohort." A finviz score is just a number; it doesn't tell you when to ignore itself. That matters when you size positions.
Every factor cites the paper it implements (Novy-Marx 2013 quality, Loughran-McDonald 2011 NLP, Hay 2014 Phase 3 base rate, Asquith 2005 short squeeze). The engine's mathematical invariant battery runs live at /coherence — auditable on every request. We trade some opacity for being verifiable instead of credible-by-assertion.
No equity screener does this. Framler runs a Bayesian model on every Healthcare-sector ticker: anchor on Hay et al. 2014 base rates, update with log-likelihood-ratios from enrollment velocity, endpoint amendments, mechanism risk, and cash-burn runway. The output is a colour-coded PH3 pill on every biotech card.
Finviz Elite is $39.50/month for real-time data and advanced filters. Framler has no Elite tier — the full multi-factor engine, every conformal interval, and the Phase 3 failure model are publicly readable today on every ticker, no credit card. The two are complements: use Finviz when you need a chart screener, use Framler when you need a calibrated quant score with academic citations.
Two reasons. (1) The factor pipeline reads SEC EDGAR 10-K / 20-F filings, ClinicalTrials.gov, PubMed, options and short-interest feeds — running this on 9,000 names exceeds free-tier API quotas. (2) The 1000+ are curated for liquidity and coverage of the academic factor literature. We expand as data quality allows; the universe was 234 in March 2026 and grew 4x in one cycle.
No. Framler is a fundamental + factor + Bayesian-regime engine, not a chart-pattern screener. If you need RSI / MACD / 52-week-high filters, Finviz remains the fastest tool for that. If you want to know which stocks score highly on a peer-reviewed multi-factor model with honest uncertainty intervals, Framler is the answer.
Finviz is a filter-based screener — the user chooses the criteria. Framler is a model — the engine combines factors into one composite under regime-conditional weights, surfaces confluence patterns, and outputs a 0–100 score with a confidence interval. The closest analogy is "Finviz is a spreadsheet, Framler is a forecast."
No sign-up wall. Type any of 1000+ tickers, see the full multi-factor factor breakdown, the regime context, every firing pattern, and the conformal prediction interval. Then compare with Finviz — that's the cleanest test.